Monoclonal antibodies (mAb) have had tremendous success in treating a variety of 
cancers over the past twenty years. Yet despite their widespread clinical use, 
which includes treatments for haematological malignancies, there are still no 
approved mAb therapies for multiple myeloma (MM). This is likely to change 
within the next few years with a number of mAb therapies being assessed in late 
stage clinical trials, most notably, the anti-CS-1 mAb, elotuzumab, and the 
anti-CD38 mAb, daratumumab, which are currently being evaluated in Phase III 
clinical trials for MM. In this review, we will discuss the preclinical and 
clinical development of MDX-1097, a Phase II candidate which targets cell 
membrane-associated kappa immunoglobulin free light chains expressed on the 
surface of MM cells.